Ignite Creation Date:
2024-05-05 @ 10:39 PM
Last Modification Date:
2024-10-26 @ 10:22 AM
Study NCT ID:
NCT01154335
Status:
COMPLETED
Last Update Posted:
2022-05-03
First Post:
2010-06-29
Brief Title:
Everolimus and OSI-906 for Patients With Refractory Metastatic Colorectal Cancer
Sponsor:
SCRI Development Innovations LLC
Organization:
SCRI Development Innovations LLC
Organization Data
Organization:
SCRI Development Innovations LLC
Class:
OTHER
Study ID:
SCRI GI 124
Study Type:
None
Study Domain:
None
Study Link:
None
Lead Sponsor:
SCRI Development Innovations LLC
Lead Sponsor Class:
OTHER
Responsible Party:
None
Responsible Party Title:
None
Responsible Party Type:
SPONSOR
Responsible Party Affiliation:
None
Old Name:
None
Old Organization:
None
Collaborators
| Name | Class |
|---|---|
| OSI Pharmaceuticals | INDUSTRY |
| Novartis Pharmaceuticals | INDUSTRY |